|Bid||20.68 x 0|
|Ask||20.68 x 0|
|Day's Range||20.58 - 21.67|
|52 Week Range||7.33 - 32.95|
|Beta (3Y Monthly)||5.06|
|PE Ratio (TTM)||37.32|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.09|
If you have doubts that cannabis is on its way from illegal to industrial, take a look inside Cresco Labs’ custom built, 43-thousand square-foot production facility in Joliet, Illinois.
At first glance, cannabis and cryptocurrencies seem to have a lot in common. Both comprise highly speculative markets subject to exuberant highs and crushing lows. The legality and regulation of each has languished in the gray. And to many mainstream investors, both have failed to shake synonymy with the black market.
Bank of America sees 39% upside in this marijuana stock, but a lot would need to go right for that to happen.
Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) and two other Canadian pot stocks top the list of hot tickers to watch.
Hunting for a bargain? This group of beaten-down stocks, including Aphria (TSX:APHA)(NYSE:APHA), might provide the value you're looking for.
Descartes Systems Group Inc. (TSX:DSG)(NASDAQ:DSGX) joined the tech stock rally, helping to nudge the TSX index higher this week.
Jefferies analyst Owen Bennett likes Aphria and the Green Organic Dutchman, but is less impressed by Cronos Group. Where the marijuana market is going, and how to play it.
After following the cannabis industry for a couple years, Stifel analyst Andrew Carter launched formal coverage this week of Canada’s large-cap producers. He thinks that Aurora, Tilray, and Cronos Group only merit Hold ratings.
Just how high can CBD sales climb? That's the key question facing companies and regulators as cannabis goes mainstream.
Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) has been doing well this week, but investors should be careful not to get caught up in the hype surrounding the stock.
Cronos Group stock was rising thanks to a two-notch upgrade from Bank of America Merrill Lynch, which argues that a move into the U.S. CBD market could be a huge opportunity for the company.
Altria stock hasn’t performed well this year, but Wells Fargo believes there’s still a bull case to be made for the stock, especially given the company’s valuable partnership with marijuana company Cronos Group.
Cronos Group: Rating and Target Price UpgradeCronos GroupEarly on June 5, Cronos Group (CRON) moved higher. The stock rose almost 14% when the market opened. The company was moving higher due to analysts’ positive notes about the cannabis
BAML Projects CBD Will Become $11.5 Billion Market by 2032BAML on CBDOn June 5, Bank of America Merrill Lynch upgraded Cronos Group (CRON) to a “buy,” citing its potential launch in the US market. BAML also estimated that the CBD market will